This project will examine how reimbursement incentives contribute to prescribing patterns. Using a regression discontinuity design, the project will compare the rate of administration of biosimilars between 340B and non-340B hospitals before and after the 2018 Medicare reimbursement changes created stronger incentives for 340B providers to administer biosimilars relative to non-340B providers. It also will determine if this impacted adoption of new biosimilars. The study will use the Medicare 20% sample of fee-for-service outpatient claims data and the Beneficiary Summary File, the Hospital Cost Report Information System (HCRIS) database, and the 340B Information System for data on 340B hospital participants.
The Role of Financial Incentives in Biosimilar Uptake in Medicare: Evidence from the 340B Program
Grantee Organization
Joan and Sanford I. Weill Medical College of Cornell University
Principal Investigator
Amelia Bond, Ph.D., M.H.S.
Term
1/1/21 - 6/30/22
Award Amount
$165,480
Approval Year
Related Program
Controlling Health Care Costs
Grantee Organization
Joan and Sanford I. Weill Medical College of Cornell University
Principal Investigator
Amelia Bond, Ph.D., M.H.S.
Term
1/1/21 - 6/30/22
Award Amount
$165,480
Approval Year
Related Program
Controlling Health Care Costs